Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06567314 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma
A Phase 2 study of Cutaneous Squamous Cell Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06567314: Recruiting Phase 2 study of Cutaneous Squamous Cell Carcinoma, sponsored by M.D. Anderson Cancer Center.
NCT06567314 is a Phase 2 study of Cutaneous Squamous Cell Carcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 24 participants, below the 91-participant average among 18 other Cutaneous Squamous Cell Carcinoma trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06567314, a Phase 2 study of Cutaneous Squamous Cell Carcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if ivonescimab can help to control advanced cSCC. The safety and effects of ivonescimab will also be studied.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Conditions Studied
Interventions
- DRUG Ivonescimab
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-12-02 |
| Est. Completion | 2030-09-01 |
| Phase | Phase 2 |
What NCT06567314 shows while recruiting
NCT06567314 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 91-participant average among 18 other Cutaneous Squamous Cell Carcinoma trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Cutaneous Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Ivonescimab is the first listed.
NCT06567314 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06567314 about?
NCT06567314 is a clinical study titled "Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma". To learn if ivonescimab can help to control advanced cSCC. The safety and effects of ivonescimab will also be studied.
What is the current status of trial NCT06567314?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2024-12-02. Estimated completion is 2030-09-01.
What conditions does trial NCT06567314 study?
This clinical trial studies the following conditions: Cutaneous Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06567314?
The interventions under investigation include: Ivonescimab (DRUG).
Who is sponsoring clinical trial NCT06567314?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06567314 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06567314's enrollment target sits among peer trials
24 14th of 18 higher than 5 of 18 other Cutaneous Squamous Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cutaneous Squamous Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIL Therapy in cSCC and MCC
RECRUITING · Phase 2
-
Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis)
RECRUITING · Phase 2
-
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
COMPLETED · Phase 2
-
Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI